Cogent Biosciences (COGT) Competitors $15.76 +1.01 (+6.85%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$16.14 +0.39 (+2.44%) As of 10/3/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. MRUS, TGTX, MENS, PTCT, KRYS, ACLX, ARWR, PCVX, ACAD, and PTGXShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Merus (MRUS), TG Therapeutics (TGTX), Jyong Biotech (MENS), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors Merus TG Therapeutics Jyong Biotech PTC Therapeutics Krystal Biotech Arcellx Arrowhead Pharmaceuticals Vaxcyte ACADIA Pharmaceuticals Protagonist Therapeutics Merus (NASDAQ:MRUS) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Which has more volatility & risk, MRUS or COGT? Merus has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Do analysts prefer MRUS or COGT? Merus currently has a consensus target price of $92.88, indicating a potential downside of 1.50%. Cogent Biosciences has a consensus target price of $20.00, indicating a potential upside of 26.90%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.18Cogent Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.77 Do institutionals & insiders have more ownership in MRUS or COGT? 96.1% of Merus shares are held by institutional investors. 3.7% of Merus shares are held by insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor MRUS or COGT? In the previous week, Merus had 57 more articles in the media than Cogent Biosciences. MarketBeat recorded 60 mentions for Merus and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.86 beat Merus' score of 0.24 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 10 Very Positive mention(s) 9 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MRUS or COGT more profitable? Cogent Biosciences has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Merus-685.64% -50.28% -42.00% Cogent Biosciences N/A -223.82%-89.44% Which has preferable valuation and earnings, MRUS or COGT? Merus has higher revenue and earnings than Cogent Biosciences. Merus is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M197.37-$215.33M-$5.50-17.14Cogent BiosciencesN/AN/A-$255.86M-$1.78-8.85 SummaryCogent Biosciences beats Merus on 9 of the 16 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E Ratio-8.8522.2886.9626.71Price / SalesN/A458.33604.82131.77Price / CashN/A47.8637.9061.31Price / Book11.949.9312.556.55Net Income-$255.86M-$52.80M$3.31B$277.50M7 Day Performance11.30%5.22%4.28%2.42%1 Month Performance20.77%10.61%6.90%8.63%1 Year Performance41.85%25.03%70.54%31.60% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.686 of 5 stars$15.76+6.8%$20.00+26.9%+41.9%$1.79BN/A-8.8580MRUSMerus1.1241 of 5 stars$69.19+1.4%$90.54+30.9%+82.1%$5.16B$36.13M-12.5837Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionTGTXTG Therapeutics4.3897 of 5 stars$34.97+8.0%$48.00+37.3%+65.1%$5.14B$329M94.51290MENSJyong BiotechN/A$59.53-9.3%N/AN/A$4.99BN/A0.0031High Trading VolumePTCTPTC Therapeutics3.4237 of 5 stars$60.85+0.6%$69.00+13.4%+86.2%$4.80B$806.78M8.731,410KRYSKrystal Biotech4.6773 of 5 stars$165.42+1.1%$209.00+26.3%+3.5%$4.73B$290.52M33.62210Positive NewsACLXArcellx2.2263 of 5 stars$78.22+0.5%$114.31+46.1%+8.7%$4.32B$107.94M-22.8780Insider TradeARWRArrowhead Pharmaceuticals4.1691 of 5 stars$32.05+4.4%$43.14+34.6%+91.9%$4.24B$3.55M-25.04400Insider TradePCVXVaxcyte2.4646 of 5 stars$33.47+5.4%$106.25+217.4%-61.7%$4.12BN/A-8.14160Positive NewsACADACADIA Pharmaceuticals4.4741 of 5 stars$24.53+0.5%$29.65+20.9%+44.4%$4.12B$957.80M18.44510PTGXProtagonist Therapeutics2.1551 of 5 stars$64.51+3.7%$68.08+5.5%+46.1%$3.87B$434.43M92.16120Positive News Related Companies and Tools Related Companies Merus Alternatives TG Therapeutics Alternatives Jyong Biotech Alternatives PTC Therapeutics Alternatives Krystal Biotech Alternatives Arcellx Alternatives Arrowhead Pharmaceuticals Alternatives Vaxcyte Alternatives ACADIA Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts